Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

No longer available 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
PSMA-11 × Genitourinary × Clear all
NCT03181867 2026-04-22

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
360 enrolled
Genitourinary

Prostatic Neoplasms

NCT04825652 2023-01-13

177Lu-PSMA-617 Managed Access Program for mCRPC Patients

Advanced Accelerator Applications

No longer available
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡